This federal Project Grant award of $230,312 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support research at the University of Massachusetts Medical School (UMass Medical) to investigate RNA interference and related gene regulatory mechanisms. The research aims to address key questions around how cells distinguish licensed from potentially dangerous genetic information, how argonautes and chromatin...
This federal Project Grant award of $438,629, issued by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports research to characterize fundamental mechano-molecular mechanisms of cell division. The research, conducted by the University of Massachusetts, will combine advanced live-cell imaging, molecular, and biochemical methods to investigate two key areas: the functional contributions of extremely large...
This federal Project Grant award, valued at $125,000.00, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The award will support research to uncover the molecular principles underlying the formation and functions of nuclear speckles, which are essential biomolecular condensates that regulate gene expression. The research, to be conducted at The Washington University from August 1, 2024 to July...
The University of Massachusetts Medical School was awarded a $591,414 Project Grant from the National Science Foundation Division of Molecular and Cellular Biosciences under the Biological Sciences federal grant program (CFDA 47.074) for the period February 1, 2023 through January 31, 2028. The grant will support research to uncover the regulation of low fidelity mRNA splicing through novel genomics and computational tools to identify and quantify erroneously spliced RNAs. This will provide a...
The federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,507,500 to the University of Massachusetts Medical School (UMass Medical) to expand the capabilities of third-generation DNA/RNA sequencing technologies. The project aims to generate rapid and cost-effective training libraries to allow for direct detection of common DNA damage and RNA modifications, enabling innovative...
This federal Project Grant award, valued at $1,675,000.00 and provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports a research project focused on understanding the mechanisms that control regulated cell death (RCD). The primary objectives of this 5-year project are to: 1) identify the mechanisms of regulation and coordination between apoptotic and non-apoptotic forms of cell death, 2) explore the...
This $125,000 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research to investigate the role of protein N-myristoylation in driving the DNA damage response (DDR). The key objectives are to: Examine the association between N-myristoylation, modulated by NMT1 and NMT2 enzymes, and genomic stability/DDR pathways. This includes assessing the impact on DNA repair mechanisms and...
The National Institute of General Medical Sciences (NIGMS) awarded a $528,000 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to the Sloan-Kettering Institute for Cancer Research located in New York, NY. The purpose of this 4-year grant, with a period of performance from September 30, 2024 to July 31, 2028, is to develop novel approaches to map the folding and protein occupancy of entire chromosomes with single-nucleosome resolution and single-molecule precision. The...
This is a Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) totaling $1,112,418. The award will fund research at the University of Kansas Center for Research Inc. to identify gene regulatory variants associated with ecologically and biomedically significant traits, examine the effect of environmental variation on gene expression, and study how gene regulatory networks evolve during adaptation. The...
This Project Grant award of $388,621 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support the development of novel molecular designs with therapeutic potential. The key objectives are: Developing ligand-heterocycle conjugates as targeted RNA degraders with rapid kinetics and selectivity for cancer-associated G-quadruplexes. Engineering nucleic acid polymers with (thio)phosphoramidate backbones as biostable...
This federal Project Grant award, provided by the National Institute of General Medical Sciences (NIGMS) under CFDA Program 93.859 - Biomedical Research and Research Training, supports research focused on two key areas of mammalian nuclear cell biology.
The first project area investigates the role of the tumor marker protein Ki-67 in protecting chromosomes during mitosis. The awardee, the University of Massachusetts Medical School (UMass Medical), will analyze how Ki-67 binds to and protects the genome, map the specific genomic regions impacted by its depletion, and determine the critical residues in its chromatin-binding domain. Additionally, UMass Medical will collaborate to solve the structure of the Ki-67-nucleosome complex.
The second project area examines the dynamic relocation of RNA splicing proteins and nuclear bodies in macrophages in response to pro-inflammatory stimuli. UMass Medical will investigate the key regulatory molecules and signaling events underlying these nuclear rearrangements during macrophage differentiation.
This 5-year, $1,675,000 award commenced on August 1, 2024 and is scheduled for completion on May 31, 2029.